LuciSel 80 mg Capsule

Description

Discover LuciSel Selpercatinib, a breakthrough kinase inhibitor designed to effectively target and treat specific cancer types. LuciSel is indicated for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC), providing a vital treatment option for this challenging condition. Additionally, LuciSel Selpercatinib is suitable for both adult and pediatric patients aged 12 years and older who are facing advanced or metastatic RET-mutant medullary thyroid cancer (MTC) requiring systemic therapy. It also caters to those with advanced or metastatic RET fusion-positive thyroid cancer who are radioactive iodine-refractory. Revolutionize your treatment journey with LuciSel Selpercatinib, a targeted solution that harnesses the power of precision medicine to improve outcomes and enhance quality of life.